Print

Active Biotech's project 57-57 presented at EULAR in Amsterdam

2006-06-26

At the conference new pre-clinical data were presented which show that 57-57, in experimental models for rheumatoid arthritis (RA), has a significant inhibitory effect on disease development. This is reflected as decreased joint destruction and inflammation.
An additive inhibitory effect on disease development is achieved when 57-57 is combined with prednisolone. Prednisolone is an anti-inflammatory corticosteroid widely used for the treatment of various inflammatory disorders.
The results strengthen the further clinical development of 57-57 for the treatment of SLE and RA, alone or in combination with prednisolone.
57-57 has been given the international generic name (INN) paquinimod by the WHO.
For further information and to view the complete poster "Paquinimod Inhibits Disease Development of Collagen Induced Arthritis in Mice", visit www.activebiotech.com .
Lund, June 26, 2006
Active Biotech AB (publ)
Sven Andréasson
President and CEO
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB
Box 724, 220 07 Lund
Sweden
Tel +46 (0) 46-19 20 00
Fax +46 (0) 46-19 20 50

pdf



Back